UNPACKED

← Frontpage

**When the Vitamin Shop Starts Selling GLP-1 Access**

5h ago · 4 sources · distribution

Holland & Barrett just stepped deeper into the weight management conversation. The retailer has partnered with clinical weight management provider Phlo, which provides GLP-1 drugs like Wegovy and Mounjaro. The services will be featured across stores and online. Holland & Barrett will signpost customers toward clinically supervised weight management journeys, but it will not proactively direct or prescribe medical routes.

The timing is not random. Holland & Barrett’s own data shows 55% of UK adults wish they could manage their weight better. 64% are actively managing their weight. 33% are actively trying to lose weight. In the UK, 30% of adults are obese and 4% of households have at least one GLP-1 user.

GLP-1 is not fringe anymore. Experts say weight-loss drugs are already changing food and drink consumption patterns. Fast&Up calls it an entirely new nutrition cohort. Roughly 1 in 10 people develop at least one new nutritional deficiency after six months on a GLP-1 drug. That is a flashing neon sign for supplements, fortified foods, and metabolic health products.

Why it matters. Retail is becoming the bridge between pharma and food. If 4% of households already include a GLP-1 user, brands that ignore this cohort risk missing a fast-forming demand pocket. The next battle is not just fewer calories. It is nutrient density, muscle support, metabolic health, and smart reformulation for smaller appetites.

Key facts

  • Holland & Barrett has partnered with clinical weight management services provider Phlo, which provides GLP-1 drugs such as Wegovy and Mounjaro, with services featured across stores and online.
  • Holland & Barrett will signpost customers toward clinically supervised weight management journeys but will not proactively direct or prescribe medical routes.
  • Holland & Barrett’s consumer data shows 55% of UK adults wish they could manage their weight better, 64% are actively managing their weight and 33% are actively trying to lose weight.
  • In the UK, 30% of adults are obese and 4% of households have at least one GLP-1 user.
  • Research shows roughly one in 10 people have at least one new nutritional deficiency after taking a GLP-1 drug for six months.
  • Healthy ageing is expanding into mainstream food and drink, with Nestlé launching its first-ever drinks line aligned with the healthy longevity trend.
  • By 2032, the elderly nutrition market is expected to reach $43.1bn, according to Serena Aboutboul, head of Nestlé’s nutrition business.
  • Metabolic health is moving into the mainstream in the age of GLP-1 weight-loss drugs and blood glucose monitors, creating opportunities for fortified everyday products.
  • The global brain health supplements market is forecast to grow at a CAGR of 13% between 2025 and 2030, with memory representing around 25% of the segment.
  • In a study of 98 adults aged 60–80, 12 weeks of supplementation with Seppic’s strawberry leaf extract led to a 23% reduction in memory errors versus placebo and an 11% reduction in perceived stress after six weeks.
  • The rise of GLP-1 therapies is creating an entirely new nutrition cohort, according to Fast&Up Co-Founder Vijayaraghavan Venugopal at the Growth Asia Summit 2026.
  • Weight-loss drugs are already starting to change consumption patterns in food and drink, according to experts speaking ahead of a Food Manufacture webinar.
  • 55%
  • 64%
  • 33%
  • 30%
  • 4%
  • 1 in 10
  • 890 million
  • 2.5 billion

Coverage